NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The Global Digital Health Market is projected to grow from USD 288.55 billion in…
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy…
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®…
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision…
CONVOKE was the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia…
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in…
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory…
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 9,…
TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader…